Viewpoint Molecular Targeting
Pharmaceuticals, 2500 Crosspark Rd, Coralville, Iowa, 52241, United States, 1-10 Employees
Phone Number: 31********
Who is VIEWPOINT MOLECULAR TARGETING
Viewpoint Molecular Targeting is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents. The Companys leading -particle radio...
Read More
-
Headquarters: 2500 Crosspark Rd, Coralville, Iowa, 52241, United States
-
Date Founded: 2008
-
Employees: 1-10
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 8731
|
NAICS Code: 541714 |
Show More
Does something look wrong? Fix it. | View contact records from VIEWPOINT MOLECULAR TARGETING
Viewpoint Molecular Targeting Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Viewpoint Molecular Targeting
Answer: Viewpoint Molecular Targeting's headquarters are located at 2500 Crosspark Rd, Coralville, Iowa, 52241, United States
Answer: Viewpoint Molecular Targeting's phone number is 31********
Answer: Viewpoint Molecular Targeting's official website is https://viewpointmt.com
Answer: Viewpoint Molecular Targeting's revenue is $5 Million to $10 Million
Answer: Viewpoint Molecular Targeting's SIC: 8731
Answer: Viewpoint Molecular Targeting's NAICS: 541714
Answer: Viewpoint Molecular Targeting has 1-10 employees
Answer: Viewpoint Molecular Targeting is in Pharmaceuticals
Answer: Viewpoint Molecular Targeting contact info: Phone number: 31******** Website: https://viewpointmt.com
Answer: Viewpoint Molecular Targeting is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents. The Companys leading -particle radiotherapies are designed to deliver powerful alpha radiation specifically to cancer cells utilizing specialized targeting peptides. Viewpoint is also developing complementary diagnostics that utilize the same targeting peptide which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments. The Companys melanoma (VMT01) and neuroendocrine tumor (VMT--NET) programs are entering Phase 1 imaging studies, to be followed by Phase 1/2a therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at two leading academic institutions.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month